# Latache details Jan. 7 board slate and seeks to reshape Oncoclínicas governance

*Fund nominates new chair, replaces most current directors and keeps CEO in transitional board role.*

- Published: 2025-12-17
- Section: Insights
- Tags: Activist Investors, Boards, Brazil stocks, corporate governance, healthcare, Novo Mercado, Oncoclínicas
- URL: https://brazilstockguide.com/insights/latache-details-jan-7-board-slate-and-seeks-to-reshape-oncoclinicas-governance/

![](https://i0.wp.com/brazilstockguide.com/wp-content/uploads/2025/12/Oncoclinicas.jpg?fit=1024%2C400&ssl=1)

**By Brazil Stock Guide –** The governance dispute at **Oncoclínicas do Brasil Serviços Médicos S.A. (B3: ONCO3)** moved into a decisive phase after shareholders linked to Latache disclosed the **full list of nominees for a new board of directors**, formalizing a proposal to replace the company’s top supervisory body ahead of an extraordinary shareholders’ meeting.

The slate will be put to a vote and calls for the **removal of the entire current board** and the election of a **seven-member council**, down from nine, following a request by Latache-managed funds that together hold about **14.6% of the company’s share capital**.

**Change at the to**p

Under the proposal, **Marcelo Gasparino da Silva** would become **chair of the board**, replacing current chairman **David Castelblanco**. Gasparino already sits on the board as an independent director and has held senior governance roles at large listed and state-controlled companies, including Petrobras, Vale and Eletrobras.

**Who exits, who stays**

If approved, the new slate would remove **Castelblanco**, **Allen McMichael Gibson**, **Clarissa Maria de Cerqueira Mathias**, **Eric Winer** and **Marcelo del Vigna** from the board. Only **Bruno Lemos Ferrari**, Oncoclínicas’ chief executive officer, and **Marcel Cecchi Vieira**, an independent director and partner at Latache Capital, would remain from the current lineup.

Ferrari, who currently serves as both CEO and vice chair, would continue on the board as **vice chairman**, preserving a direct link between management and oversight during the transition. The proposal includes a **succession mechanism** under which Ferrari would automatically become board chair if he steps down from the CEO role in the future.

**New board profile**

In addition to Gasparino, Ferrari and Cecchi Vieira, the slate includes **Andreas Ignacio Keller Sarmiento**, **Eduardo Soares do Couto Filho**, **Marcelo Curti** and **Sergio Alexandre Figueiredo Clemente**. According to documents released to the market, **six of the seven nominees meet Novo Mercado independence criteria**, pointing to a more independent and financially oriented board.

**Investor focus**

Latache argues that a full board reset is needed to unlock value, improve efficiency, cut costs and strengthen governance at a company built through acquisitions and operating with a capital-intensive structure. Oncoclínicas’ management said it merely forwarded the shareholders’ proposal to the meeting without expressing a view on the nominees.

---

Source: Brazil Stock Guide, https://brazilstockguide.com/insights/latache-details-jan-7-board-slate-and-seeks-to-reshape-oncoclinicas-governance/